山东省人民政府网站显示，根据《山东省科学技术奖励办法》规定，经省科学技术奖励评审委员会评审、省科学技术奖励委员会审定和省科技厅审核，2017年度山东省科学技术奖励出炉，山东省眼科研究所史伟云教授获得山东省科学技术最高奖，成为两位最高奖的获得者之一。

作为全国人大代表，山东省眼科研究所所长、党委书记，中华医学会眼科学分会常委、角膜病组组长，山东省泰山学者攀登计划专家，史伟云教授已从事眼科医学三十多年。近年来，他先后荣获中华眼科学会杰出成就奖、吴阶平—保罗·杨森医学药学奖、美国眼科学会成就奖等重量级奖项，是当下中国大陆眼科学领域最具代表性的专家之一。

据了解，史伟云教授首次提出的睫状体－虹膜通路，是引起角膜移植排斥另一途径的创新理论，并据此研发了我国首个具有独立知识产权的眼内植入缓释药物，获得CFDA药物临床试验批件。

他还创新深板层角膜移植治疗圆锥角膜的方法，打破了圆锥角膜只能行穿透性移植的传统观点。同时，与导师谢立信院士一起提出“不同真菌在角膜内存在不同生长方式”创新理论，打破了不能应用板层角膜移植治疗真菌性角膜炎的传统观点，使手术长期成功率超过95％。创造性应用多层羊膜移植治疗基质坏死型角膜炎，使这一世界难题取得突破性进展。

目前，史伟云教授已累计为全国30余省市的1万多名疑难角膜病患者实现复明，成为国内极少独立完成万余例疑难角膜移植手术的眼科专家。

史伟云，现任山东省眼科研究所党委书记、所长，山东省眼科医院院长，是山东省泰山学者攀登计划专家、山东省有突出贡献的中青年专家、山东省首届医学领军人才、第十三届全国人民代表大会代表、中华医学会眼科分会第十一届委员会常务委员、角膜病学组组长，中华眼科学分会专家委员，国务院特殊津贴享受者。

史伟云教授1989年开始跟随我国著名眼科专家谢立信院士攻读硕、博士，并获眼科学博士学位。2000年赴美国，跟随世界角膜病大师Kaufman教授继续角膜病的基础研究工作。2007年被青岛大学、2008年被山东大学分别聘为博士生导师。

史伟云教授从事眼科基础研究及临床诊治工作30余年，是山东大学、青岛大学、济南大学、潍坊医学院眼科学教授和博士生导师，兼任《中华眼科杂志》副总编辑，《中华眼视光学与视觉科学杂志》、《中国眼耳鼻喉科杂志》、《临床眼科杂志》、《眼科》编委、山东省眼科学分会副主任委员。

史伟云教授在临床工作方面，具有丰富的临床经验和娴熟的眼科显微手术技巧，能熟练完成各类疑难和复杂的眼前段手术。

Congratulations! Prof. Weiyun SHI Won the Highest Science and Technology Award of Shandong Province

As reported on the official website of People’s Government of Shandong Province, according to the regulations in Reward Measures for Science and Technology Awards of Shandong Province, after the evaluation by the Evaluation Committee of the Provincial Science and Technology Awards, the approval by the Committee of the Provincial Science and Technology Awards and the review by the Department of Science and Technology of Shandong Province, the Shandong Provincial Science and Technology Awards of 2017 are published. Prof. Weiyun SHI of Shandong Eye Institute won the Highest Science and Technology Award of Shandong Province, becoming one of the two highest prize winners.

Prof. SHI, as a deputy to the National People’s Congress, the director and the secretary of the Party Committee of Shandong Eye Institute, a member of the Standing Committee of the Ophthalmology Society of Chinese Medical Association, the leader of the Corneal Group and an expert of Taishan Scholar Program of Shandong Province, has been engaged in ophthalmology for more than 30 years. In recent years, he has received many important awards such as the Outstanding Achievement Award of Chinese Ophthalmology Society, Wu Jieping Medical Research Award–Paul Janssen Pharmaceutical Research Award, the Achievement Award of American Academy of Ophthalmology. Professor SHI is one of the most representative experts in ophthalmology in mainland China.

The iris-ciliary body pathway, first proposed by Prof. SHI, is an innovative theory for corneal graft rejection. Based on this research achievement, he developed the first ocular implantable sustained-release drug with independent intellectual property in China and gained the clinical trial permission for drugs from CFDA.

Prof. SHI also made innovations in deep lamellar keratoplasty to treat keratoconus, breaking the traditional view that keratoconus can only be treated by penetrating keratoplasty. Prof. SHI also proposed an innovative theory that “different fungi have different growth patterns in the cornea” with Academician Lixin XIE, who is his supervisor, breaking the traditional view that lamellar keratoplasty cannot be used to treat fungal keratitis and achieving a long-term surgery success rate of more than 95%. The creative application of multilayer amniotic membrane transplantation by Prof. SHI is a breakthrough to the worldwide problem of treating necrotizing stromal keratitis.

Up to now, Prof. SHI has helped more than 10,000 patients with difficult corneal diseases from more than 30 provinces and cities nationwide to regain sight. Prof. SHI is one of the few ophthalmologists in China that have performed more than 10,000 difficult corneal transplantation surgeries independently.